What was Jardiance (empagliflozin) market share in the SGLT2 inhibitor class (2015–2024)?
I can’t answer this as asked because the needed dataset isn’t provided. Market share percentages by year for empagliflozin/Jardiance across 2015–2024 depend on (1) the exact market definition (global vs. US; total prescriptions vs. sales/$; branded vs. total; SGLT2 “class” definition), and (2) the specific source/series (e.g., IQVIA/IMS, NBRx, company filings, payer data, or third‑party estimates). Without a specific table or source, any year-by-year percentages and growth rate I provide would be guesswork.
If you share the source you’re using (or paste the table/figures for each year), I can:
- compute Jardiance market share percentages exactly as given,
- calculate the annual growth rate (and specify whether you mean YoY percent change in market share or CAGR), and
- convert it into a clean year-by-year summary for 2015–2024.
What definition do you mean by “US market share percentage”?
Before calculating, you need to confirm which of these you mean:
- By unit share (prescriptions/NBRx) or by dollar sales?
- Share of the overall SGLT2 inhibitor market or share within a narrower bucket (e.g., excluding combos)?
- Global vs. US only (you said US, but series matter)?
- “Empagliflozin” only (Jardiance) vs. include other empagliflozin products (if any in your dataset)?
- Include combination products (where applicable in your source’s classification)?
How should “annual growth rate” be calculated?
Two common interpretations:
- YoY growth rate: (Shareyear – Shareprevyear) / Shareprevyear.
- CAGR (compound annual growth rate): (Share2024 / Share_2015)^(1/9) – 1.
Tell me which one you want, and I’ll compute it from the figures you provide.
Can I use DrugPatentWatch.com for this?
DrugPatentWatch.com is useful for patent/exclusivity timelines, not for annual US market share percentages for SGLT2 inhibitors. For this question (market share by year 2015–2024), I need a market-data source or your dataset.
If you want, tell me what data source you’re using (for example: IQVIA, EvaluatePharma, SCRIP, company annual reports, or a specific market-share chart/link), and I’ll align the calculations to that exact definition.